Redeye provides an in-depth review of Episurf Medical’s Q1 report and events during and after the qu...
Redeye comments on OncoZenge’s announcement of an exclusive licensing agreement with Avernus Pharma ...
Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever an...
Redeye updates on Invisio ahead of Q1-results (due 6 May) where we expect continued solid YoY growth...
Redeye provides a brief comment on Smart Eye’s newly proposed long-term incentive program for employ...
Q1e: Clean paper EBIT of ~PLN 15m Price hikes, but demand soft Fair value range of SEK 34-75 Our ea...
Redeye shares its preview of BONESUPPORT’s Q1 2025 results, due April 24.
Redeye returns with an updated take on NextCell following the inconclusive interim analysis, which h...
Redeye reviews its valuation of IRLAB following the missed top-line readout with pirepemat in PD-fal...
Redeye sees the acquisition of Welotec as a strategically sound move with relatively low risks.
XVIVO is likely to enter 2025 with a modest quarter during a period of macro-economic worries.
Q1 likely flat, limited uptick in Q2e Targets challenging - likely to land below Recovery postponed ...
We believe organic growth could be negative y/y for Q1 2025.
Redeye comments on the acquisition announced this morning, where Dynavox Group acquires its long-tim...
Redeye provides a preview ahead of Sleep Cycles’ Q1 2025 results.
